Emery P, van Keep M, Beard S, Graham C, Miles L, Jugl SM, Gunda P, Halliday A, Marzo-Ortega H. Cost effectiveness of secukinumab for the treatment of active ankylosing spondylitis in the UK. Pharmacoeconomics. 2018 Aug;36(8):1015-27. doi: 10.1007/s40273-018-0675-9
Buchanan V, Sullivan W, Graham C, Miles L, Jugl SM, Gunda P, Halliday A, Kirkham B. Cost effectiveness of secukinumab for the treatment of active psoriatic arthritis in the UK. Pharmacoeconomics. 2018 Jul;36(7):867-78. doi: 10.1007/s40273-018-0674-x.
Augustin M, Krieger T, McBride D, Graham C, Melzer N, Kneidl J, Gutknecht M, Neidhardt K. Kosten-effektivität von secukinumab in der induktionstherapie der psoriasis in Deutschland. Poster presented at the 49th German Society of Dermatology (DDG) Conference; April 26, 2017. Berlin, Germany. [abstract] J Dtsch Dermatol Ges. 2017 Apr; 15(S1):130-1. doi: 10.1111/ddg.13213
Earnshaw SR, Graham CN, Ettinger B, Amonkar MM, Lynch NO, Middelhoven H. Cost-effectiveness of bisphosphonate therapies for women with postmenopausal osteoporosis: implications of improved persistence with less frequently administered oral bisphosphonates. Curr Med Res Opin. 2007 Oct 1;23(10):2517-29.